1. Home
  2. LVO vs MAIA Comparison

LVO vs MAIA Comparison

Compare LVO & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo LiveOne Inc.

LVO

LiveOne Inc.

HOLD

Current Price

$4.49

Market Cap

65.9M

ML Signal

HOLD

Logo MAIA Biotechnology Inc.

MAIA

MAIA Biotechnology Inc.

HOLD

Current Price

$1.36

Market Cap

79.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LVO
MAIA
Founded
2009
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Restaurants
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
65.9M
79.0M
IPO Year
2010
2022

Fundamental Metrics

Financial Performance
Metric
LVO
MAIA
Price
$4.49
$1.36
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$11.50
N/A
AVG Volume (30 Days)
42.7K
584.3K
Earning Date
06-17-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
78.57
33.33
EPS
N/A
N/A
Revenue
$77,144,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$23.04
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.43
$0.87
52 Week High
$7.19
$3.19

Technical Indicators

Market Signals
Indicator
LVO
MAIA
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
LVO
MAIA

About LVO LiveOne Inc.

LiveOne Inc creator-first, music, entertainment and technology platform focused on delivering premium experiences and content world'wide through paid users and live and virtual events. It is in the acquisition, distribution and monetization of live music events, Internet radio, podcasting/vodcasting and music-related membership, streaming and video content. It provide services through a dedicated over-the-top application powered by Slacker (LiveOne App) called LiveOne. The company has three operating segments, PodcastOne, Slacker and Media Group. The company generates majority of revenue from PodcastOne. The Company's operations are based in the United States.

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.

Share on Social Networks: